Study of ceftriaxone and amoxicillin treatment in patients with acute coronary syndrome, non-ST-elevation myocardial infarction, or ST-elevation myocardial infarction

3 1 1 1

What is this study about?

This study focuses on treating patients with acute coronary syndrome, which includes conditions such as ST-elevation myocardial infarction (heart attack with specific changes in heart electrical activity), non-ST-elevation myocardial infarction (another type of heart attack), and coronary artery disease (narrowing of heart blood vessels). The purpose is to determine if antibiotic treatment can reduce complications in patients with these heart conditions.

The study will use two different antibiotics: ceftriaxone, which is given through an intravenous infusion (through a vein), and amoxicillin, which is taken as tablets by mouth. These medications will target specific bacteria that have been found in the fatty deposits that build up in the arteries of patients with heart attacks.

During the study, patients will receive antibiotic treatment for up to two weeks. The medications will be used to target bacteria that are commonly found in complicated artery blockages. Patients will be monitored for heart-related events and complications over several years after receiving the treatment.

1 Initial treatment phase

After being diagnosed with heart attack (myocardial infarction) and agreeing to participate, you will receive treatment in two forms:

Intravenous infusion of ceftriaxone (2g solution)

Oral tablets of amoxicillin (500mg film-coated tablets)

This treatment targets bacteria that may be involved in heart vessel blockages

2 Heart examination procedure

You will undergo an angiography – a procedure to examine your heart blood vessels

This examination is part of standard care for your condition

3 3-month follow-up

Your health status will be evaluated after 3 months

The medical team will check for any heart or brain-related events that may have occurred

4 12-month follow-up

A comprehensive health assessment will be conducted after one year

This evaluation will check for any:
– Heart-related deaths
– New heart attacks
– Hospital stays due to severe heart failure
– Stroke or mini-stroke episodes

5 Long-term follow-up

Additional health assessments will be performed at 2 years and 5 years after treatment

These evaluations will monitor your long-term heart and brain health

Who Can Join the Study?

  • Patient must be 18 years of age or older
  • Patient must have been diagnosed with either:
    • STEMI (heart attack where a major heart artery is completely blocked)
    • NSTEMI (heart attack where a heart artery is partially blocked)
  • Patient must be scheduled for angiography (a procedure to examine blood vessels of the heart)
  • Patient must have at least 3 of the following risk factors:
    • High blood pressure (hypertension)
    • Diabetes
    • Moderate kidney problems (kidney filtration rate below 60ml/min)
    • Peripheral arterial disease (narrowing of arteries outside the heart)
    • Multiple blocked heart arteries
    • Previous heart attack
    • Previous stroke or mini-stroke (TIA)
  • Patient must be able to provide informed consent (agree to participate after understanding study details)

Who Cannot Join the Study?

  • History of allergic reaction to antibiotics that will be used in the study
  • Current or recent (within 2 weeks) use of antibiotics
  • Severe kidney problems (as this may affect how the body processes the medication)
  • Severe liver disease that could interfere with medication metabolism
  • Pregnancy or breastfeeding
  • Participation in another clinical trial within the past 30 days
  • Life expectancy less than 12 months due to other medical conditions
  • Unable to provide informed consent (written permission to participate in the study)
  • History of severe gastrointestinal problems that could affect medication absorption
  • Active bacterial infection requiring immediate antibiotic treatment
  • Known blood disorders that could affect study results
  • Immunodeficiency conditions (weakened immune system)
  • History of organ transplantation
  • Severe mental illness that could affect ability to follow study procedures

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Pirkanmaan hyvinvointialue Tampere Finland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Finland Finland
Not yet recruiting
01.11.2025

Trial locations

Based on the provided trial information about antibiotic treatment in acute coronary syndrome, I cannot specifically identify the exact medications used, as they are not explicitly mentioned in the source data. The trial appears to involve antibiotics targeting bacteria found in atherosclerotic plaques, but the specific antibiotic names are not provided in the source material.

Without more detailed information about the specific medications used in this trial, I cannot provide accurate descriptions of the treatments involved. To maintain accuracy and avoid speculation, I would need additional data about which particular antibiotics or other medications were used in this clinical trial.

Non-ST-elevation myocardial infarction (NSTEMI) – A type of heart attack where the coronary artery is partially blocked, reducing blood flow to part of the heart muscle. The blockage typically occurs due to a buildup of fatty deposits, cholesterol, and other substances that form plaque in the arteries. The condition develops when this plaque ruptures, causing blood clots to form and restrict blood flow.

ST-elevation myocardial infarction (STEMI) – A severe type of heart attack where one of the heart’s major arteries is completely blocked, preventing blood from reaching a large area of the heart. This blockage leads to the death of heart muscle tissue in the affected area. The condition typically causes intense chest pain and other symptoms that develop suddenly.

Coronary artery disease – A condition where the major blood vessels that supply the heart become damaged or diseased. It typically develops over many years as fatty deposits build up inside the coronary arteries, causing them to narrow and become less flexible. This process, known as atherosclerosis, reduces blood flow to the heart muscle and can lead to chest pain and other symptoms.

Heart failure – A chronic condition where the heart cannot pump blood effectively enough to meet the body’s needs. The heart continues to work but becomes weaker over time or too stiff to fill properly. This leads to fluid buildup in the lungs and other body tissues, causing symptoms like shortness of breath and fatigue.

Stroke – A condition that occurs when blood flow to part of the brain is interrupted, either by a blockage or a burst blood vessel. This disruption of blood flow prevents brain tissue from getting oxygen and nutrients. Brain cells begin to die within minutes of oxygen deprivation, leading to various symptoms depending on which area of the brain is affected.

Transient Ischemic Attack (TIA) – A temporary interruption of blood flow to part of the brain, causing brief stroke-like symptoms. Unlike a stroke, a TIA typically resolves within minutes to hours. The blood flow disruption is temporary and does not cause permanent brain damage.

Trial ID:
2025-522136-14-00
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • Study of dapagliflozin and semaglutide to reverse prediabetes to normal blood sugar levels in patients with coronary artery disease

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark
  • A Study of Intravenous Lidocaine to Reduce Inflammation in Patients Undergoing Heart Valve or Coronary Artery Bypass Surgery with Heart-Lung Machine

    Recruiting

    2 1 1
    Spain